Clinical Research, Pharma & Healthcare FinancingVedanta Biosciences Phase 3 VE303 Study Continues as PlannedBusiness WireApril 3, 2026April 6, 2026 by Business WireApril 3, 2026April 6, 2026011 Independent Data Monitoring Committee Recommendation was Based on Review of Safety and Efficacy; Enrollment Expected to Complete in 2H 2026 Vedanta Biosciences, a late clinical-stage...
